Hospital
ST Joseph Mercy Chelsea INC
ST Joseph Mercy Chelsea INC was paid $6.89M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99285, emergency room visit (most serious) — 30% of everything it billed.
33Billing provider infoST JOSEPH MERCY CHELSEA INC
CHELSEA, MI 48118
CHELSEA, MI 48118
33aNPI1992761985assigned 04/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.89M
24GClaims191,323
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#68 of 86
Median peer was paid$21.55M
This provider vs. median0.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GUSHO, MICHAEL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,495 | $703K | |
| 2019 | 17,786 | $672K | |
| 2020 | 21,189 | $826K | |
| 2021 | 32,786 | $1.26M | |
| 2022 | 34,951 | $1.19M | |
| 2023 | 39,473 | $1.30M | |
| 2024incomplete | 26,643 | $933K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 30% | 5,677 | 5,356 | $2.09M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 5,949 | 5,690 | $1.23M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.4% | 5,136 | 5,000 | $650K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 8.5% | 6,148 | 5,674 | $589K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.6% | 2,382 | 2,313 | $321K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.6% | 3,289 | 3,012 | $247K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.5% | 5,332 | 4,450 | $172K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 1,402 | 1,332 | $131K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 1,943 | 1,877 | $129K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 4,129 | 3,543 | $125K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 3,250 | 3,140 | $120K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 788 | 778 | $80K |
146 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 241 | $79K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.1% | 1,068 | $78K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,262 | $75K |
| 80061 | Lipid panel | <1% | 1,757 | $57K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 532 | $54K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 936 | $46K |
| 20610 | <1% | 245 | $39K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 77 | $37K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,715 | $36K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 585 | $35K |
| 71045 | Radiologic examination, chest; single view | <1% | 872 | $35K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,900 | $29K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,220 | $26K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,070 | $26K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,380 | $22K |
| 76830 | Ultrasound, transvaginal | <1% | 357 | $21K |
| 80053 | Comprehensive metabolic panel | <1% | 11,396 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,564 | $19K |
| 93975 | <1% | 159 | $19K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 401 | $19K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,056 | $18K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 143 | $16K |
| G0378 | Hospital observation service, per hour | <1% | 800 | $16K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 25 | $14K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 135 | $13K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,601 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 461 | $11K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 554 | $10K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 66 | $10K |
| 85027 | <1% | 3,313 | $8K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 48 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,455 | $7K |
| 82728 | <1% | 550 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,527 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 783 | $5K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 230 | $4K |
| 70496 | <1% | 33 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 316 | $4K |
| 73630 | <1% | 326 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,716 | $3K |
| 84439 | <1% | 864 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,708 | $3K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 77 | $3K |
| 84466 | <1% | 309 | $2K | |
| 82607 | <1% | 255 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 177 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 176 | $2K |
| 86900 | <1% | 448 | $2K | |
| 84702 | <1% | 2,070 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $2K |
| 83735 | <1% | 2,928 | $2K | |
| 87428 | <1% | 48 | $2K | |
| 83540 | <1% | 394 | $2K | |
| 72100 | <1% | 67 | $2K | |
| 0012A | <1% | 51 | $1K | |
| 93971 | <1% | 29 | $1K | |
| 86140 | <1% | 958 | $1K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 78 | $1K |
| 86850 | <1% | 433 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 873 | $1K |
| 84703 | <1% | 2,663 | $1K | |
| 73030 | <1% | 148 | $1K | |
| 73610 | <1% | 112 | $1K | |
| 90837 | Psychotherapy session, about an hour | <1% | 14 | $1K |
| 85610 | <1% | 1,340 | $1K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 43 | $966.99 |
| 76770 | <1% | 12 | $959.40 | |
| 0011A | <1% | 55 | $928.24 | |
| 73110 | <1% | 47 | $913.67 | |
| 73130 | <1% | 54 | $881.43 | |
| 71271 | <1% | 12 | $702.51 | |
| Q3014 | Telehealth originating site facility fee | <1% | 44 | $652.61 |
| 85652 | <1% | 788 | $652.34 | |
| 97161 | <1% | 14 | $587.30 | |
| 83690 | <1% | 3,298 | $573.61 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 219 | $570.52 |
| 85730 | <1% | 491 | $562.37 | |
| 80076 | <1% | 330 | $549.52 | |
| 81001 | <1% | 4,071 | $535.83 | |
| 73564 | <1% | 24 | $488.63 | |
| 74018 | <1% | 27 | $486.29 | |
| 83880 | <1% | 143 | $453.96 | |
| 86901 | <1% | 450 | $380.46 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 26 | $363.80 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 32 | $329.18 |
| 81003 | <1% | 2,295 | $293.69 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 26 | $274.56 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 195 | $266.19 |
| 73562 | <1% | 28 | $239.19 | |
| 85379 | <1% | 1,078 | $226.70 | |
| 86780 | <1% | 13 | $113.72 | |
| 84484 | <1% | 2,951 | $109.88 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 133 | $95.80 |
| 83605 | <1% | 730 | $95.64 | |
| 88142 | <1% | 12 | $86.90 | |
| 87340 | <1% | 12 | $81.72 | |
| 82248 | <1% | 62 | $71.13 | |
| 87081 | <1% | 62 | $68.08 | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,420 | $61.32 |
| 82570 | <1% | 12 | $39.70 | |
| 85007 | <1% | 69 | $37.21 | |
| 87186 | <1% | 25 | $36.68 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,289 | $30.66 |
| 82565 | <1% | 13 | $20.16 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,512 | $17.00 |
| 84100 | <1% | 46 | $15.10 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,161 | $12.90 |
| 87077 | <1% | 16 | $11.48 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,788 | $9.97 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,515 | $4.92 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,152 | $3.18 |
| 96376 | <1% | 1,280 | $2.99 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 204 | $1.34 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 972 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,390 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 99 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 576 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 193 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 52 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 15 | $0.00 |
| 84145 | 0% | 12 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 146 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 3,237 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 2,658 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 654 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 234 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 985 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 2,864 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 105 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 313 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 121 | $0.00 |
| J3490 | Unclassified drugs | 0% | 641 | $0.00 |
| 83520 | 0% | 210 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 269 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 127 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 104 | $0.00 |
| 82803 | 0% | 43 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 13 | $0.00 |
| A9270 | Non-covered item or service | 0% | 296 | $0.00 |
| 87430 | 0% | 13 | $0.00 | |
| 87040 | 0% | 46 | $0.00 | |
| 70498 | 0% | 32 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 12 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 46 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 21 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGUSHO, MICHAEL (SR REIMBURSEMENT MANAGEMENT ANALYST)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.